# UProtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/uprotech

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.u-protech.com
- Latest round: Angel (Sep 2, 2022)
- Investors on record: 2

## About

Based in Hangzhou, China, and established in 2021, UProtech is a biopharmaceutical company that focuses on the R&D of proteolysis targeting chimera (PROTAC) drugs. It is equipped with 1,700 offices and laboratories. And, its team members public over 250 papers on Science Citation Index (SCI). It was co-established by professor Jianping Jin, and Shixian Lin, and professor Jianping Jin find the ubiquitin E1 enzyme, Uba6, and specific E2 enzyme Use1.

It engages in the R&D of PROTAC drugs, especially ubiquitin ligase ligands for tumors and immune diseases. The PROTAC drugs can provide solutions for mutation targeting, catalyst volume onset, and drug resistance.

## Funding rounds

- Angel, Sep 2, 2022 — Zheshang Venture Capital, Shanghai Industrial Investment

## Investors

- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Angel
- Shanghai Industrial Investment (https://capitalatlas.ai/funds/shanghai-industrial-investment) — Angel